Exposure-response relationship during vedolizumab induction therapy in adults with ulcerative colitis

被引：0
|
作者：
Rosario, M. [1 ]
French, J. [2 ]
Dirks, N. [2 ]
Milton, A. [1 ]
Fox, I. [1 ]
Gastonguay, M. [2 ]
机构：
[1] Takeda Pharmaceut Int Co, Clin Pharmacol, Cambridge, MA USA
[2] Metrum Res Grp LLC, Biotechnol, Tariffville, CT USA
来源：
JOURNAL OF CROHNS & COLITIS | 2014年 / 8卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P489
引用
收藏
页码：S270 / S271
页数：3
相关论文
共 50 条
  • [1] Exposure-Response Relationship of Vedolizumab Treatment in Adults With Ulcerative Colitis
    French, Jonathan
    Rosario, Maria
    Dirks, Nathanael L.
    Milton, Ashley
    Fox, Irving
    Gastonguay, Marc R.
    GASTROENTEROLOGY, 2014, 146 (05) : S592 - S592
  • [2] Vedolizumab Exposure-Response Relationship During Induction Therapy in Adults With Crohn's Disease
    French, Jonathan
    Rosario, Maria
    Dirks, Nathanael L.
    Milton, Ashley
    Fox, Irving
    Gastonguay, Marc R.
    GASTROENTEROLOGY, 2014, 146 (05) : S592 - S593
  • [3] Exposure-response relationship of vedolizumab subcutaneous treatment in patients with ulcerative colitis: VISIBLE 1
    Rosario, M.
    Polhamus, D.
    Dirks, N.
    Lock, R.
    Yao, X.
    Chen, J.
    Chen, C.
    Sun, W.
    Feagan, B.
    Sandborn, W.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S377 - S378
  • [4] Vedolizumab Efficacy Exposure-Response Relationship for Ulcerative Colitis Patients (GEMINI I) Based on Causal Inference Analysis
    Osterman, Mark
    Gastonguay, Marc R.
    Lasch, Karen
    Barocas, Morris A.
    Rosario, Maria
    Wilbur, Jayson D.
    Dirks, Nathanael L.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S294 - S294
  • [5] Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
    Feagan, Brian G.
    Rutgeerts, Paul
    Sands, Bruce E.
    Hanauer, Stephen
    Colombel, Jean-Frederic
    Sandborn, William J.
    Van Assche, Gert
    Axler, Jeffrey
    Kim, Hyo-Jong
    Danese, Silvio
    Fox, Irving
    Milch, Catherine
    Sankoh, Serap
    Wyant, Tim
    Xu, Jing
    Parikh, Asit
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (08): : 699 - 710
  • [6] A Markov Transition Model for Characterization of Exposure-Response of Tofacitinib During Maintenance Therapy in Patients with Ulcerative Colitis
    Tsuchiwata, Shinichi
    Suzuki, Akiyuki
    Mukherjee, Arnab
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S9 - S9
  • [7] Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis
    Vande Casteele, Niels
    Jeyarajah, Jenny
    Jairath, Vipul
    Feagan, Brian G.
    Sandborn, William J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (09) : 1814 - +
  • [8] Exposure-response relationship of vedolizumab after 6 weeks of treatment in adults with Crohn's disease
    Rosario, M.
    French, J.
    Dirks, N.
    Milton, A.
    Fox, I.
    Gastonguay, M.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S270 - S270
  • [9] Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis
    Adedokun, Omoniyi J.
    Xu, Zhenhua
    Liao, Sam
    Strauss, Richard
    Reinisch, Walter
    Feagan, Brian G.
    Sandborn, William J.
    CLINICAL THERAPEUTICS, 2020, 42 (01) : 157 - 174
  • [10] Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease
    Rosario, Maria
    French, Jonathan L.
    Dirks, Nathanael L.
    Sankoh, Serap
    Parikh, Asit
    Yang, Huyuan
    Danese, Silvio
    Colombel, Jean-Frederic
    Smyth, Michael
    Sandborn, William J.
    Feagan, Brian G.
    Reinisch, Walter
    Sands, Bruce E.
    Sans, Miguel
    Fox, Irving
    JOURNAL OF CROHNS & COLITIS, 2017, 11 (08): : 921 - 929
12345